Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis.
Martin GraversenSönke DetlefsenJon Kroll BjerregaardClaus Wilki FristrupPer PfeifferMichael Bau MortensenPublished in: Therapeutic advances in medical oncology (2018)
PIPAC is feasible and well tolerated, may stabilize the quality of life in patients with end-stage PM and may induce histological and cytological regression.This study is registered at www.clinicaltrials.gov [ClinicalTrials.gov identifier: NCT02320448].